Biomarker Insights & Resistance Mechanisms in KRAS G12C-Mutated mCRC: Findings from the Phase 3 CodeBreaK 300 Study
- Identify key baseline co-alterations and their impact on treatment response
- Characterize emergent alterations at progression
- Inform future combination strategies